Dopamine D2 Receptor Biomarkers for Brain Dopamine Levels ID: 2022-045
An innovative method for diagnosing and monitoring neurological and psychiatric conditions through a simple blood test.
Technology Overview:
This technology introduces a groundbreaking approach to measure brain dopamine levels indirectly by analyzing the expression of dopamine D2 receptors on monocytes in the blood. This method offers a non-invasive, cost-effective alternative to traditional positron emission tomography (PET) scans. Developed with NIH funding and managed by Brigham Young University's Technology Transfer Office, it employs a microfluidics device for precise measurement, paving the way for widespread clinical application.
Key Advantages
- Non-invasive measurement of brain dopamine levels.
- Cost-effective alternative to PET scans.
- Scalable and precise through microfluidics technology.
- Potentially faster diagnosis and monitoring of diseases.
- Supports personalized treatment strategies in healthcare.
Problems Solved
- High cost and invasiveness of current dopamine level measurement techniques.
- Lack of accessible diagnostics for neurological and psychiatric conditions.
- Difficulty in monitoring disease progression and treatment efficacy.
Market Applications
- Diagnosis and monitoring of Parkinson's disease.
- Management of psychiatric disorders.
- Treatment and monitoring of addiction.
- Personalized medicine through objective measurement of treatment response.
Stage of Development
This technology is in the prototyping stage. A device using microfluidics technology has been developed to detect D2R expression in blood samples, and ongoing studies are evaluating its effectiveness in both rodent models and human subjects.
Additional Information
Technology ID: 2022-045
Sell Sheet: Download the Sell Sheet here
Marketing Analysis: Link to Market Analysis here
Date Published: March 18, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report